ALK-Abelló AS
- BID
31.48
- ASK
31.78
- 953 Units944 Units
- 07/21, 18:04:47 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
24.53%
Market Cap
-
P/E Ratio
42.31
Dividend Yield
0.70 %
Earnings per Share
0.73 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 31.46 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 06:01:56 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 31.72 | 31.38 |
| PREV. DAY'S PRICE | 31.48 | (07/20) |
| CHANGE DAY BEFORE | -0.02 | -0.06 % |
| 52 WEEK HIGH / LOW | 36.36 (06/15) | 22.6 (08/12) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 0.30 | 0.49 | 0.73 | 0.87 | 0.98 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.21 | 0.21 | 0.21 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.70 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 46.05 | 43.20 | 42.31 | 36.98 | 32.81 |
PRICE - BOOK RATIO | 5.03 | 6.56 | 7.86 | - | - |
PRICE - SALES RATIO | 4.64 | 6.37 | 8.03 | - | - |
PRICE - CASH FLOW RATIO | 33.57 | 29.06 | 27.91 | - | - |
Master Data
| WKN | A3DHX9 |
| ISIN | DK0061802139 |
| SYMBOL | 4AJ0 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ALK-ABELLO AS DK -,50 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -1.13 % | -4.95 % | 12.59 % | 5.71 % | 24.53 % | 228.09 % | 58.83 % | 7.66 % |
| HIGH | 32.38 | 34.38 | 36.36 | 36.36 | 36.36 | 36.36 | 36.36 | 36.36 |
| LOW | 31.44 | 31.44 | 29.52 | 25.94 | 22.60 | 8.99 | 8.99 | 25.94 |
Dividende
pro Aktie
Company profile
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.
Structured products for ALK-Abelló AS
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.